AstraZeneca plc (NYSE:AZN) Expected to Announce Quarterly Sales of $6.63 Billion

Wall Street analysts predict that AstraZeneca plc (NYSE:AZN) will announce $6.63 billion in sales for the current fiscal quarter, Zacks reports. Two analysts have made estimates for AstraZeneca’s earnings, with the lowest sales estimate coming in at $6.55 billion and the highest estimate coming in at $6.71 billion. AstraZeneca reported sales of $6.42 billion during the same quarter last year, which would suggest a positive year over year growth rate of 3.3%. The company is expected to announce its next earnings results on Thursday, February 13th.

According to Zacks, analysts expect that AstraZeneca will report full-year sales of $24.07 billion for the current financial year, with estimates ranging from $23.79 billion to $24.43 billion. For the next financial year, analysts anticipate that the firm will post sales of $26.36 billion, with estimates ranging from $25.66 billion to $27.11 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of research firms that follow AstraZeneca.

AstraZeneca (NYSE:AZN) last announced its earnings results on Thursday, October 24th. The company reported $0.50 earnings per share for the quarter, beating analysts’ consensus estimates of $0.45 by $0.05. The firm had revenue of $6.13 billion for the quarter, compared to analyst estimates of $6.07 billion. AstraZeneca had a net margin of 8.42% and a return on equity of 38.63%. The company’s revenue for the quarter was up 14.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.71 EPS.

A number of equities research analysts have recently weighed in on AZN shares. Cowen reaffirmed an “outperform” rating and set a $55.00 target price (up previously from $48.00) on shares of AstraZeneca in a research note on Monday, December 2nd. Leerink Swann started coverage on shares of AstraZeneca in a research note on Friday, November 22nd. They set an “outperform” rating and a $57.00 target price on the stock. Liberum Capital reaffirmed a “hold” rating on shares of AstraZeneca in a research note on Thursday, October 24th. Argus lifted their target price on shares of AstraZeneca to $50.00 and gave the company a “buy” rating in a research note on Wednesday, August 14th. Finally, DZ Bank lowered shares of AstraZeneca from a “hold” rating to a “sell” rating in a research note on Tuesday, September 3rd. Four research analysts have rated the stock with a sell rating, five have assigned a hold rating and twelve have issued a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $48.72.

Shares of AZN traded up $0.06 during trading hours on Monday, reaching $47.68. 2,477,478 shares of the company traded hands, compared to its average volume of 4,042,849. The company’s fifty day moving average price is $47.34 and its two-hundred day moving average price is $43.55. The company has a market capitalization of $125.10 billion, a price-to-earnings ratio of 27.56, a price-to-earnings-growth ratio of 1.67 and a beta of 0.47. The company has a quick ratio of 0.70, a current ratio of 0.92 and a debt-to-equity ratio of 1.29. AstraZeneca has a 12 month low of $35.30 and a 12 month high of $49.22.

In other AstraZeneca news, major shareholder Plc Astrazeneca acquired 425,000 shares of the company’s stock in a transaction that occurred on Monday, October 7th. The shares were acquired at an average price of $19.00 per share, with a total value of $8,075,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Large investors have recently bought and sold shares of the stock. Manchester Financial Inc. bought a new stake in AstraZeneca during the second quarter worth about $25,000. Prime Capital Investment Advisors LLC bought a new stake in AstraZeneca during the third quarter worth about $34,000. Oakworth Capital Inc. boosted its stake in AstraZeneca by 141.0% during the second quarter. Oakworth Capital Inc. now owns 964 shares of the company’s stock worth $40,000 after acquiring an additional 564 shares in the last quarter. San Francisco Sentry Investment Group CA boosted its stake in AstraZeneca by 37.6% during the second quarter. San Francisco Sentry Investment Group CA now owns 967 shares of the company’s stock worth $40,000 after acquiring an additional 264 shares in the last quarter. Finally, Venturi Wealth Management LLC bought a new stake in AstraZeneca during the third quarter worth about $46,000. 17.50% of the stock is currently owned by institutional investors and hedge funds.

About AstraZeneca

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Read More: Why do commodities matter?

Get a free copy of the Zacks research report on AstraZeneca (AZN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AstraZeneca (NYSE:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.